Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Prevnar Family by Year
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — U.S. reported YoY (%) (%)
Pfizer Prevnar Family: -2.0% in FY2025, down 1.0 pts from a year earlier.
Latest, FY2025
-2.0%
Period ended Dec 31, 2025
Change on a year earlier
-1.0 pts
-1.0% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below
Where the FY2025 figure comes from
“|| Prevnar family (c) | 6,494 | 6,411 | 1% | 1% | 4,151 | 4,233 | (2%) | 2,342 | 2,178 | 8% | 7%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Prevnar Family (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/prevnar-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.